Tuesday, June 06, 2017 6:39:54 PM
Recent CLDX News
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria • GlobeNewswire Inc. • 04/17/2024 12:01:00 PM
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference • GlobeNewswire Inc. • 03/08/2024 12:00:00 PM
- Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 03/05/2024 03:30:00 PM
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 03/05/2024 03:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:10:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 09:09:03 PM
- Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock • GlobeNewswire Inc. • 03/01/2024 02:14:47 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 09:10:14 PM
- Celldex Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2024 01:18:41 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2024 12:05:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:01:57 PM
- Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/26/2024 12:01:00 PM
- Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria • GlobeNewswire Inc. • 02/24/2024 07:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:05:55 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:17:46 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 05:52:38 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 04:48:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:38:19 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 02:41:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/08/2024 03:11:32 PM
- Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/06/2024 09:01:00 PM
- Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 • GlobeNewswire Inc. • 02/05/2024 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:44 PM
- Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference • GlobeNewswire Inc. • 11/27/2023 09:15:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM